Fundies. English
Segment disclosures
Company overviewMaravai LifeSciences Holdings, Inc.
Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.
Revenue · Reported segment facts
49 dimension combinations 743 retained observations 27 reported periods
Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.
Intersegment Elimination · Biologics Safety Testing Segment
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:IntersegmentEliminationMember;us-gaap:StatementBusinessSegmentsAxis=mrvi:BiologicsSafetyTestingSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | -3000 | USD | 20250318 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 0 | USD | 20250318 | Open filing evidence |
Intersegment Elimination · Cygnus Segment
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:IntersegmentEliminationMember;us-gaap:StatementBusinessSegmentsAxis=mrvi:CygnusSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | -3000 | USD | 20260226 | Open filing evidence |
Intersegment Elimination · Nucleic Acid Production Segment
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:IntersegmentEliminationMember;us-gaap:StatementBusinessSegmentsAxis=mrvi:NucleicAcidProductionSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 0 | USD | 20250318 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | -7000 | USD | 20250318 | Open filing evidence |
Intersegment Elimination · Tri Link Segment
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:IntersegmentEliminationMember;us-gaap:StatementBusinessSegmentsAxis=mrvi:TriLinkSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 0 | USD | 20260226 | Open filing evidence |
Operating Segments · Biologics Safety Testing Segment
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=mrvi:BiologicsSafetyTestingSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-07-01 – 2025-09-30 | 16277000 | USD | 20251107 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 50689000 | USD | 20251107 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 16312000 | USD | 20250811 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 34412000 | USD | 20250811 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 18100000 | USD | 20250512 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 62840000 | USD | 20250318 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 15181000 Restated | USD | 20251107 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 48181000 Restated | USD | 20251107 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 14837000 Restated | USD | 20250811 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 33000000 Restated | USD | 20250811 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 18163000 | USD | 20250512 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 64179000 | USD | 20250318 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 15638000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 48863000 | USD | 20241112 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 15651000 | USD | 20240808 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 33225000 | USD | 20240808 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 69932000 | USD | 20250318 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 16382000 | USD | 20231108 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 54509000 | USD | 20231108 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 17484000 | USD | 20230808 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 38127000 | USD | 20230808 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 68417000 | USD | 20240229 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 16626000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 52483000 | USD | 20221104 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 54897000 | USD | 20230228 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 14114000 | USD | 20211115 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 40772000 | USD | 20211115 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 44416000 | USD | 20220301 | Open filing evidence |
Operating Segments · Cygnus Segment
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=mrvi:CygnusSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 16773000 | USD | 20260807 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 35134000 | USD | 20260807 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 18361000 | USD | 20260508 | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 65956000 | USD | 20260226 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 16312000 | USD | 20260807 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 34412000 | USD | 20260807 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 18100000 | USD | 20260508 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 62840000 | USD | 20260226 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 64179000 | USD | 20260226 | Open filing evidence |
Operating Segments · Nucleic Acid Production Segment
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=mrvi:NucleicAcidProductionSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-07-01 – 2025-09-30 | 25353000 | USD | 20251107 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 85188000 | USD | 20251107 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 31085000 | USD | 20250811 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 59835000 | USD | 20250811 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 28750000 | USD | 20250512 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 196345000 | USD | 20250318 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 53844000 Restated | USD | 20251107 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 154446000 | USD | 20251107 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 54586000 Restated | USD | 20250811 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 100602000 Restated | USD | 20250811 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 46016000 | USD | 20250512 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 224769000 | USD | 20250318 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 51228000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 165944000 | USD | 20241112 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 53265000 | USD | 20240808 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 114716000 | USD | 20240808 | Open filing evidence |
| 2023-01-01 – 2023-03-31 | 61451000 | USD | 20240509 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 813076000 | USD | 20250318 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 225255000 | USD | 20230808 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 448905000 | USD | 20230808 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 223650000 | USD | 20220506 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 712520000 | USD | 20240229 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 183055000 | USD | 20211115 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 499962000 | USD | 20211115 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 192738000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 316907000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 124169000 | USD | 20220506 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 207597000 | USD | 20230228 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 68019000 | USD | 20211115 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 129645000 | USD | 20211115 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 72602000 | USD | 20220301 | Open filing evidence |
Operating Segments · Protein Detection Segment
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=mrvi:ProteinDetectionSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 0 | USD | 20240229 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 0 | USD | 20240229 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 0 | USD | 20221104 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 0 | USD | 20221104 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 0 | USD | 20220805 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 0 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 18959000 | USD | 20240229 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 5283000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 18959000 | USD | 20221104 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 7046000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 13676000 | USD | 20220805 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 22881000 | USD | 20230228 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 6089000 | USD | 20211115 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 16404000 | USD | 20211115 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 4117000 | USD | 20210811 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 10315000 | USD | 20210811 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 26122000 | USD | 20220301 | Open filing evidence |
Operating Segments · Tri Link Segment
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=mrvi:TriLinkSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 34669000 | USD | 20260807 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 82145000 | USD | 20260807 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 47476000 | USD | 20260508 | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 119787000 | USD | 20260226 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 31085000 | USD | 20260807 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 59835000 | USD | 20260807 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 28750000 | USD | 20260508 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 196345000 | USD | 20260226 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 224769000 | USD | 20260226 | Open filing evidence |
Latin And Central America · Biologics Safety Testing Segment
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=mrvi:LatinAndCentralAmericaMember;us-gaap:StatementBusinessSegmentsAxis=mrvi:BiologicsSafetyTestingSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 246000 | USD | 20260508 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 237000 | USD | 20251107 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 470000 | USD | 20251107 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 122000 | USD | 20250811 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 233000 | USD | 20250811 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 111000 | USD | 20260508 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 452000 | USD | 20250318 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 79000 Restated | USD | 20251107 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 385000 Restated | USD | 20251107 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 86000 | USD | 20250811 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 306000 | USD | 20250811 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 220000 | USD | 20250512 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 323000 | USD | 20250318 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 74000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 230000 | USD | 20241112 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 67000 | USD | 20240808 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 156000 | USD | 20240808 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 664000 | USD | 20250318 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 189000 | USD | 20231108 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 417000 | USD | 20231108 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 129000 | USD | 20230808 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 228000 | USD | 20230808 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 663000 | USD | 20230228 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 171000 | USD | 20211115 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 528000 | USD | 20211115 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 302000 | USD | 20230228 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 45000 | USD | 20211115 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 225000 | USD | 20211115 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 366000 | USD | 20220301 | Open filing evidence |
Latin And Central America · Cygnus Segment
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=mrvi:LatinAndCentralAmericaMember;us-gaap:StatementBusinessSegmentsAxis=mrvi:CygnusSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 193000 | USD | 20260807 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 439000 | USD | 20260807 | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 693000 | USD | 20260226 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 122000 | USD | 20260807 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 233000 | USD | 20260807 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 452000 | USD | 20260226 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 323000 | USD | 20260226 | Open filing evidence |
Latin And Central America · Nucleic Acid Production Segment
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=mrvi:LatinAndCentralAmericaMember;us-gaap:StatementBusinessSegmentsAxis=mrvi:NucleicAcidProductionSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 83000 | USD | 20260508 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 59000 | USD | 20251107 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 177000 | USD | 20251107 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 83000 | USD | 20250811 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 118000 | USD | 20250811 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 35000 | USD | 20260508 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 210000 | USD | 20250318 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 46000 Restated | USD | 20251107 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 168000 | USD | 20251107 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 35000 Restated | USD | 20250811 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 122000 Restated | USD | 20250811 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 87000 | USD | 20250512 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 204000 | USD | 20250318 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 31000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 143000 | USD | 20241112 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 48000 | USD | 20240808 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 112000 | USD | 20240808 | Open filing evidence |
| 2023-01-01 – 2023-03-31 | 64000 | USD | 20240509 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 144000 | USD | 20250318 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 35000 | USD | 20220805 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 50000 | USD | 20220805 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 15000 | USD | 20220506 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 56000 | USD | 20230228 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 18000 | USD | 20211115 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 35000 | USD | 20211115 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 0 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 17000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 17000 | USD | 20220506 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 23000 | USD | 20230228 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 0 | USD | 20211115 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 19000 | USD | 20211115 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 27000 | USD | 20220301 | Open filing evidence |
Latin And Central America · Protein Detection Segment
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=mrvi:LatinAndCentralAmericaMember;us-gaap:StatementBusinessSegmentsAxis=mrvi:ProteinDetectionSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-01-01 – 2021-12-31 | 123000 | USD | 20220301 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 29000 | USD | 20211115 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 123000 | USD | 20211115 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 44000 | USD | 20210811 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 94000 | USD | 20210811 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 149000 | USD | 20220301 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 30000 | USD | 20211115 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 95000 | USD | 20211115 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 25000 | USD | 20210811 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 65000 | USD | 20210811 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 249000 | USD | 20220301 | Open filing evidence |
Latin And Central America · Tri Link Segment
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=mrvi:LatinAndCentralAmericaMember;us-gaap:StatementBusinessSegmentsAxis=mrvi:TriLinkSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 193000 | USD | 20260807 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 276000 | USD | 20260807 | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 278000 | USD | 20260226 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 83000 | USD | 20260807 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 118000 | USD | 20260807 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 210000 | USD | 20260226 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 204000 | USD | 20260226 | Open filing evidence |
Asia Pacific · Biologics Safety Testing Segment
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=srt:AsiaPacificMember;us-gaap:StatementBusinessSegmentsAxis=mrvi:BiologicsSafetyTestingSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 5963000 | USD | 20260508 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 4642000 | USD | 20251107 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 16187000 | USD | 20251107 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 5135000 | USD | 20250811 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 11545000 | USD | 20250811 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 6410000 | USD | 20260508 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 20056000 | USD | 20250318 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 4708000 Restated | USD | 20251107 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 14937000 | USD | 20251107 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 4004000 Restated | USD | 20250811 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 10229000 Restated | USD | 20250811 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 6225000 | USD | 20250512 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 21725000 | USD | 20250318 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 5022000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 15820000 | USD | 20241112 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 4977000 | USD | 20240808 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 10798000 | USD | 20240808 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 24286000 | USD | 20250318 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 5605000 | USD | 20230808 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 13933000 | USD | 20230808 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 8328000 | USD | 20220506 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 26471000 | USD | 20240229 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 5441000 | USD | 20211115 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 19844000 | USD | 20211115 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 6735000 | USD | 20220506 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 17946000 | USD | 20230228 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 4204000 | USD | 20211115 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 13356000 | USD | 20211115 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 5562000 | USD | 20210512 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 12964000 | USD | 20220301 | Open filing evidence |
Asia Pacific · Cygnus Segment
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=srt:AsiaPacificMember;us-gaap:StatementBusinessSegmentsAxis=mrvi:CygnusSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 5618000 | USD | 20260807 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 11581000 | USD | 20260807 | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 21988000 | USD | 20260226 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 5135000 | USD | 20260807 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 11545000 | USD | 20260807 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 20056000 | USD | 20260226 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 21725000 | USD | 20260226 | Open filing evidence |
Asia Pacific · Nucleic Acid Production Segment
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=srt:AsiaPacificMember;us-gaap:StatementBusinessSegmentsAxis=mrvi:NucleicAcidProductionSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 1909000 | USD | 20260508 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 3697000 | USD | 20251107 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 10867000 | USD | 20251107 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 3023000 | USD | 20250811 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 7170000 | USD | 20250811 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 4147000 | USD | 20260508 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 69322000 | USD | 20250318 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 18210000 | USD | 20251107 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 52536000 | USD | 20251107 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 19415000 | USD | 20250811 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 34326000 | USD | 20250811 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 14911000 | USD | 20250512 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 75716000 | USD | 20250318 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 19601000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 55495000 | USD | 20241112 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 12343000 | USD | 20240808 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 35894000 | USD | 20240808 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 85508000 | USD | 20250318 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 29737000 | USD | 20230808 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 42604000 | USD | 20230808 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 12867000 | USD | 20220506 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 54114000 | USD | 20240229 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 5332000 | USD | 20211115 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 33977000 | USD | 20211115 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 20760000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 28645000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 7885000 | USD | 20220506 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 21444000 | USD | 20230228 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 3759000 | USD | 20211115 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 13296000 | USD | 20211115 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 6843000 | USD | 20220301 | Open filing evidence |
Asia Pacific · Protein Detection Segment
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=srt:AsiaPacificMember;us-gaap:StatementBusinessSegmentsAxis=mrvi:ProteinDetectionSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-01-01 – 2021-12-31 | 3068000 | USD | 20240229 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 795000 | USD | 20211115 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 3068000 | USD | 20211115 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 913000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 2273000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 1360000 | USD | 20220506 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 3783000 | USD | 20230228 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 901000 | USD | 20211115 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 2730000 | USD | 20211115 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 722000 | USD | 20210811 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 1829000 | USD | 20210811 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 3784000 | USD | 20220301 | Open filing evidence |
Asia Pacific · Tri Link Segment
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=srt:AsiaPacificMember;us-gaap:StatementBusinessSegmentsAxis=mrvi:TriLinkSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 3701000 | USD | 20260807 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 5610000 | USD | 20260807 | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 19486000 | USD | 20260226 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 3023000 | USD | 20260807 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 7170000 | USD | 20260807 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 69322000 | USD | 20260226 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 75716000 | USD | 20260226 | Open filing evidence |
North America · Biologics Safety Testing Segment
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=srt:NorthAmericaMember;us-gaap:StatementBusinessSegmentsAxis=mrvi:BiologicsSafetyTestingSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 7736000 | USD | 20260508 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 7339000 | USD | 20251107 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 21401000 | USD | 20251107 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 6767000 | USD | 20250811 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 14062000 | USD | 20250811 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 7295000 | USD | 20260508 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 26723000 | USD | 20250318 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 6916000 Restated | USD | 20251107 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 20810000 Restated | USD | 20251107 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 6801000 Restated | USD | 20250811 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 13894000 Restated | USD | 20250811 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 7093000 | USD | 20250512 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 26596000 | USD | 20250318 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 6622000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 20392000 | USD | 20241112 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 6677000 | USD | 20240808 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 13770000 | USD | 20240808 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 27354000 | USD | 20250318 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 6583000 | USD | 20231108 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 21274000 | USD | 20231108 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 7172000 | USD | 20230808 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 14691000 | USD | 20230808 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 25686000 | USD | 20230228 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 7203000 | USD | 20211115 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 20052000 | USD | 20211115 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 6437000 | USD | 20210811 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 12849000 | USD | 20210811 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 6412000 | USD | 20210512 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 21787000 | USD | 20230228 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 6035000 | USD | 20211115 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 16217000 | USD | 20211115 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 5057000 | USD | 20210811 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 10182000 | USD | 20210811 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 5125000 | USD | 20210512 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 18984000 | USD | 20220301 | Open filing evidence |
North America · Cygnus Segment
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=srt:NorthAmericaMember;us-gaap:StatementBusinessSegmentsAxis=mrvi:CygnusSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 6638000 | USD | 20260807 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 14374000 | USD | 20260807 | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 27152000 | USD | 20260226 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 6767000 | USD | 20260807 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 14062000 | USD | 20260807 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 26723000 | USD | 20260226 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 26596000 | USD | 20260226 | Open filing evidence |
North America · Nucleic Acid Production Segment
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=srt:NorthAmericaMember;us-gaap:StatementBusinessSegmentsAxis=mrvi:NucleicAcidProductionSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 27953000 | USD | 20260508 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 17687000 | USD | 20251107 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 63533000 | USD | 20251107 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 23872000 | USD | 20250811 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 45846000 | USD | 20250811 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 21974000 | USD | 20260508 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 100367000 | USD | 20250318 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 27703000 | USD | 20251107 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 79417000 | USD | 20251107 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 25436000 | USD | 20250811 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 51714000 | USD | 20250811 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 26278000 | USD | 20250512 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 114459000 | USD | 20250318 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 27893000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 88961000 | USD | 20241112 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 27653000 | USD | 20240808 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 61068000 | USD | 20240808 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 312119000 | USD | 20250318 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 82015000 | USD | 20230808 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 161433000 | USD | 20230808 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 79418000 | USD | 20220506 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 280369000 | USD | 20230228 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 73622000 | USD | 20211115 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 207469000 | USD | 20211115 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 65715000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 133847000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 68132000 | USD | 20220506 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 115216000 | USD | 20230228 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 36814000 | USD | 20211115 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 82523000 | USD | 20211115 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 20839000 | USD | 20210811 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 45708000 | USD | 20210811 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 24869000 | USD | 20210512 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 49757000 | USD | 20220301 | Open filing evidence |
North America · Protein Detection Segment
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=srt:NorthAmericaMember;us-gaap:StatementBusinessSegmentsAxis=mrvi:ProteinDetectionSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-01-01 – 2021-12-31 | 11016000 | USD | 20220301 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 3067000 | USD | 20211115 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 11016000 | USD | 20211115 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 4197000 | USD | 20210811 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 7949000 | USD | 20210811 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 3752000 | USD | 20210512 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 13343000 | USD | 20220301 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 3735000 | USD | 20211115 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 9577000 | USD | 20211115 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 2413000 | USD | 20210811 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 5842000 | USD | 20210811 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 3429000 | USD | 20210512 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 15284000 | USD | 20220301 | Open filing evidence |
North America · Tri Link Segment
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=srt:NorthAmericaMember;us-gaap:StatementBusinessSegmentsAxis=mrvi:TriLinkSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 24646000 | USD | 20260807 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 52599000 | USD | 20260807 | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 85225000 | USD | 20260226 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 23872000 | USD | 20260807 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 45846000 | USD | 20260807 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 100367000 | USD | 20260226 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 114459000 | USD | 20260226 | Open filing evidence |
EMEA · Biologics Safety Testing Segment
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=us-gaap:EMEAMember;us-gaap:StatementBusinessSegmentsAxis=mrvi:BiologicsSafetyTestingSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 4416000 | USD | 20260508 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 4059000 | USD | 20251107 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 12631000 | USD | 20251107 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 4288000 | USD | 20250811 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 8572000 | USD | 20250811 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 4284000 | USD | 20260508 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 15609000 | USD | 20250318 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 3478000 Restated | USD | 20251107 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 12049000 Restated | USD | 20251107 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 3946000 Restated | USD | 20250811 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 8571000 Restated | USD | 20250811 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 4625000 | USD | 20250512 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 15532000 | USD | 20250318 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 3919000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 12418000 | USD | 20241112 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 3928000 | USD | 20240808 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 8499000 | USD | 20240808 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 17628000 | USD | 20250318 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 4069000 | USD | 20231108 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 13344000 | USD | 20231108 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 4697000 | USD | 20220506 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 15597000 | USD | 20230228 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 3811000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 12059000 | USD | 20221104 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 3899000 | USD | 20210811 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 8248000 | USD | 20210811 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 4349000 | USD | 20220506 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 14862000 | USD | 20230228 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 3603000 | USD | 20210811 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 7144000 | USD | 20210811 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 12102000 | USD | 20220301 | Open filing evidence |
EMEA · Cygnus Segment
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=us-gaap:EMEAMember;us-gaap:StatementBusinessSegmentsAxis=mrvi:CygnusSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 4324000 | USD | 20260807 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 8740000 | USD | 20260807 | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 16123000 | USD | 20260226 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 4288000 | USD | 20260807 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 8572000 | USD | 20260807 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 15609000 | USD | 20260226 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 15532000 | USD | 20260226 | Open filing evidence |
EMEA · Nucleic Acid Production Segment
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=us-gaap:EMEAMember;us-gaap:StatementBusinessSegmentsAxis=mrvi:NucleicAcidProductionSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 17531000 | USD | 20260508 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 3910000 | USD | 20251107 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 10611000 | USD | 20251107 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 4107000 | USD | 20250811 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 6701000 | USD | 20250811 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 2594000 | USD | 20260508 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 26446000 | USD | 20250318 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 7885000 Restated | USD | 20251107 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 22325000 | USD | 20251107 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 9700000 Restated | USD | 20250811 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 14440000 Restated | USD | 20250811 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 4740000 | USD | 20250512 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 34390000 | USD | 20250318 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 3703000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 21345000 | USD | 20241112 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 13221000 | USD | 20240808 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 17642000 | USD | 20240808 | Open filing evidence |
| 2023-01-01 – 2023-03-31 | 4421000 | USD | 20230509 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 415298000 | USD | 20250318 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 113461000 | USD | 20220805 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 244811000 | USD | 20220805 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 131350000 | USD | 20230509 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 377325000 | USD | 20230228 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 103929000 | USD | 20211115 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 257873000 | USD | 20211115 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 106046000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 153944000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 47898000 | USD | 20220506 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 69637000 | USD | 20230228 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 27083000 | USD | 20211115 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 32731000 | USD | 20211115 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 3599000 | USD | 20210811 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 5648000 | USD | 20210811 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 15975000 | USD | 20220301 | Open filing evidence |
EMEA · Protein Detection Segment
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=us-gaap:EMEAMember;us-gaap:StatementBusinessSegmentsAxis=mrvi:ProteinDetectionSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-01-01 – 2021-12-31 | 4752000 | USD | 20230228 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 1392000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 4752000 | USD | 20221104 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 1892000 | USD | 20210811 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 3360000 | USD | 20210811 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 1468000 | USD | 20220506 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 5606000 | USD | 20230228 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 1423000 | USD | 20211115 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 4002000 | USD | 20211115 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 957000 | USD | 20210811 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 2579000 | USD | 20210811 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 6805000 | USD | 20220301 | Open filing evidence |
EMEA · Tri Link Segment
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=us-gaap:EMEAMember;us-gaap:StatementBusinessSegmentsAxis=mrvi:TriLinkSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 6129000 | USD | 20260807 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 23660000 | USD | 20260807 | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 14798000 | USD | 20260226 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 4107000 | USD | 20260807 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 6701000 | USD | 20260807 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 26446000 | USD | 20260226 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 34390000 | USD | 20260226 | Open filing evidence |
Biologics Safety Testing Segment
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=mrvi:BiologicsSafetyTestingSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 18361000 | USD | 20260508 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 16277000 | USD | 20251107 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 50689000 | USD | 20251107 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 16312000 | USD | 20250811 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 34412000 | USD | 20250811 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 18100000 | USD | 20260508 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 62840000 | USD | 20250318 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 15181000 Restated | USD | 20251107 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 48181000 Restated | USD | 20251107 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 14837000 Restated | USD | 20250811 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 33000000 Restated | USD | 20250811 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 18163000 | USD | 20250512 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 64176000 | USD | 20250318 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 15637000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 48860000 | USD | 20241112 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 15649000 | USD | 20240808 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 33223000 | USD | 20240808 | Open filing evidence |
| 2023-01-01 – 2023-03-31 | 17574000 | USD | 20240509 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 69932000 | USD | 20250318 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 16382000 | USD | 20231108 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 54509000 | USD | 20231108 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 17484000 | USD | 20230808 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 38127000 | USD | 20230808 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 20643000 | USD | 20230509 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 68417000 | USD | 20240229 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 16626000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 52483000 | USD | 20221104 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 18208000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 35857000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 17649000 | USD | 20220506 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 54897000 | USD | 20230228 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 14114000 | USD | 20211115 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 40772000 | USD | 20211115 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 12364000 | USD | 20210811 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 26658000 | USD | 20210811 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 14294000 | USD | 20210512 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 44416000 | USD | 20220301 | Open filing evidence |
Biologics Safety Testing Segment · Operating Segments
Statement Business Segments · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=mrvi:BiologicsSafetyTestingSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-03-31 | 18163000 | USD | 20240509 | Open filing evidence |
| 2023-01-01 – 2023-03-31 | 17574000 | USD | 20240509 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 17484000 | USD | 20220805 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 38127000 | USD | 20220805 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 20643000 | USD | 20230509 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 18208000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 35857000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 17649000 | USD | 20220506 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 12364000 | USD | 20210811 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 26658000 | USD | 20210811 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 14293000 | USD | 20210512 | Open filing evidence |
Biologics Safety Testing Segment · Latin And Central America
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=mrvi:BiologicsSafetyTestingSegmentMember;srt:StatementGeographicalAxis=mrvi:LatinAndCentralAmericaMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-03-31 | 220000 | USD | 20240509 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 323000 | USD | 20240229 | Open filing evidence |
| 2023-01-01 – 2023-03-31 | 89000 | USD | 20240509 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 664000 | USD | 20240229 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 189000 | USD | 20221104 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 417000 | USD | 20221104 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 129000 | USD | 20220805 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 228000 | USD | 20220805 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 99000 | USD | 20230509 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 663000 | USD | 20240229 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 171000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 528000 | USD | 20221104 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 204000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 357000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 153000 | USD | 20220506 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 114000 | USD | 20210811 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 180000 | USD | 20210811 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 66000 | USD | 20210512 | Open filing evidence |
Biologics Safety Testing Segment · Asia Pacific
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=mrvi:BiologicsSafetyTestingSegmentMember;srt:StatementGeographicalAxis=srt:AsiaPacificMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-03-31 | 6225000 | USD | 20240509 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 5022000 | USD | 20231108 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 15820000 | USD | 20231108 | Open filing evidence |
| 2023-01-01 – 2023-03-31 | 5821000 | USD | 20240509 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 5541000 | USD | 20231108 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 19474000 | USD | 20231108 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 5605000 | USD | 20220805 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 13933000 | USD | 20220805 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 8328000 | USD | 20230509 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 5441000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 19844000 | USD | 20221104 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 7668000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 14403000 | USD | 20220805 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 3590000 | USD | 20210811 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 9152000 | USD | 20210811 | Open filing evidence |
Biologics Safety Testing Segment · North America
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=mrvi:BiologicsSafetyTestingSegmentMember;srt:StatementGeographicalAxis=srt:NorthAmericaMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-03-31 | 7093000 | USD | 20240509 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 26596000 | USD | 20240229 | Open filing evidence |
| 2023-01-01 – 2023-03-31 | 7093000 | USD | 20240509 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 27354000 | USD | 20240229 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 6583000 | USD | 20221104 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 21274000 | USD | 20221104 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 7172000 | USD | 20220805 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 14691000 | USD | 20220805 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 7519000 | USD | 20230509 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 25686000 | USD | 20240229 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 7203000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 20052000 | USD | 20221104 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 6437000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 12849000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 6412000 | USD | 20220506 | Open filing evidence |
Biologics Safety Testing Segment · EMEA
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=mrvi:BiologicsSafetyTestingSegmentMember;srt:StatementGeographicalAxis=us-gaap:EMEAMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-03-31 | 4625000 | USD | 20240509 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 15532000 | USD | 20240229 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 3928000 | USD | 20230808 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 8499000 | USD | 20230808 | Open filing evidence |
| 2023-01-01 – 2023-03-31 | 4571000 | USD | 20240509 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 17628000 | USD | 20240229 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 4578000 | USD | 20230808 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 9275000 | USD | 20230808 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 4697000 | USD | 20230509 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 15597000 | USD | 20240229 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 3811000 | USD | 20211115 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 12059000 | USD | 20211115 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 3899000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 8248000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 4349000 | USD | 20210512 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 3830000 | USD | 20211115 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 10974000 | USD | 20211115 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 3541000 | USD | 20210512 | Open filing evidence |
Cygnus Segment
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=mrvi:CygnusSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 16773000 | USD | 20260807 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 35134000 | USD | 20260807 | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 65956000 | USD | 20260226 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 16312000 | USD | 20260807 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 34412000 | USD | 20260807 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 62840000 | USD | 20260226 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 64176000 | USD | 20260226 | Open filing evidence |
Nucleic Acid Production Segment
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=mrvi:NucleicAcidProductionSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 47476000 | USD | 20260508 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 25353000 | USD | 20251107 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 85188000 | USD | 20251107 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 31085000 | USD | 20250811 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 59835000 | USD | 20250811 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 28750000 | USD | 20260508 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 196345000 | USD | 20250318 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 53844000 Restated | USD | 20251107 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 154446000 | USD | 20251107 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 54586000 Restated | USD | 20250811 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 100602000 Restated | USD | 20250811 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 46016000 | USD | 20250512 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 224769000 | USD | 20250318 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 51228000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 165944000 | USD | 20241112 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 53265000 | USD | 20240808 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 114716000 | USD | 20240808 | Open filing evidence |
| 2023-01-01 – 2023-03-31 | 61451000 | USD | 20240509 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 813069000 | USD | 20250318 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 174881000 | USD | 20231108 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 623779000 | USD | 20231108 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 225248000 | USD | 20230808 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 448898000 | USD | 20230808 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 223650000 | USD | 20230509 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 711864000 | USD | 20240229 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 182901000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 499354000 | USD | 20221104 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 192521000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 316453000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 123932000 | USD | 20220506 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 206320000 | USD | 20230228 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 67656000 | USD | 20211115 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 128569000 | USD | 20211115 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 30424000 | USD | 20210811 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 60913000 | USD | 20210811 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 30489000 | USD | 20210512 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 72602000 | USD | 20220301 | Open filing evidence |
Nucleic Acid Production Segment · Operating Segments
Statement Business Segments · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=mrvi:NucleicAcidProductionSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-30 | 51228000 | USD | 20231108 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 165944000 | USD | 20231108 | Open filing evidence |
| 2023-01-01 – 2023-03-31 | 61451000 | USD | 20230509 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 174881000 | USD | 20231108 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 623786000 | USD | 20231108 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 223650000 | USD | 20230509 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 183055000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 499962000 | USD | 20221104 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 192738000 | USD | 20210811 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 316907000 | USD | 20210811 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 124169000 | USD | 20210512 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 30735000 | USD | 20210811 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 61626000 | USD | 20210811 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 30892000 | USD | 20210512 | Open filing evidence |
Nucleic Acid Production Segment · Latin And Central America
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=mrvi:NucleicAcidProductionSegmentMember;srt:StatementGeographicalAxis=mrvi:LatinAndCentralAmericaMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 204000 | USD | 20240229 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 31000 | USD | 20231108 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 143000 | USD | 20231108 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 48000 | USD | 20230808 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 112000 | USD | 20230808 | Open filing evidence |
| 2023-01-01 – 2023-03-31 | 64000 | USD | 20230509 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 144000 | USD | 20240229 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 65000 | USD | 20231108 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 115000 | USD | 20231108 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 35000 | USD | 20230808 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 50000 | USD | 20230808 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 15000 | USD | 20230509 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 56000 | USD | 20240229 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 18000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 35000 | USD | 20221104 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 0 | USD | 20210811 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 17000 | USD | 20210811 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 17000 | USD | 20210512 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 7000 | USD | 20210811 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 20000 | USD | 20210811 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 13000 | USD | 20210512 | Open filing evidence |
Nucleic Acid Production Segment · Asia Pacific
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=mrvi:NucleicAcidProductionSegmentMember;srt:StatementGeographicalAxis=srt:AsiaPacificMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-03-31 | 14911000 | USD | 20240509 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 19601000 | USD | 20231108 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 55495000 | USD | 20231108 | Open filing evidence |
| 2023-01-01 – 2023-03-31 | 23551000 | USD | 20240509 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 5931000 | USD | 20231108 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 48535000 | USD | 20231108 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 12867000 | USD | 20230509 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 5332000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 33977000 | USD | 20221104 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 20760000 | USD | 20210811 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 28645000 | USD | 20210811 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 7885000 | USD | 20210512 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 5979000 | USD | 20210811 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 9537000 | USD | 20210811 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 3558000 | USD | 20210512 | Open filing evidence |
Nucleic Acid Production Segment · North America
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=mrvi:NucleicAcidProductionSegmentMember;srt:StatementGeographicalAxis=srt:NorthAmericaMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-03-31 | 26278000 | USD | 20240509 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 114459000 | USD | 20240229 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 27893000 | USD | 20231108 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 88961000 | USD | 20231108 | Open filing evidence |
| 2023-01-01 – 2023-03-31 | 33415000 | USD | 20240509 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 312119000 | USD | 20240229 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 91130000 | USD | 20231108 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 252563000 | USD | 20231108 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 79418000 | USD | 20230509 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 280369000 | USD | 20240229 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 73622000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 207469000 | USD | 20221104 | Open filing evidence |
Nucleic Acid Production Segment · EMEA
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=mrvi:NucleicAcidProductionSegmentMember;srt:StatementGeographicalAxis=us-gaap:EMEAMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-03-31 | 4740000 | USD | 20240509 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 34390000 | USD | 20240229 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 3703000 | USD | 20231108 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 21345000 | USD | 20231108 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 13221000 | USD | 20230808 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 17642000 | USD | 20230808 | Open filing evidence |
| 2023-01-01 – 2023-03-31 | 4421000 | USD | 20240509 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 415298000 | USD | 20240229 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 77755000 | USD | 20231108 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 322566000 | USD | 20231108 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 113461000 | USD | 20230808 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 244811000 | USD | 20230808 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 377325000 | USD | 20240229 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 103929000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 257873000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 47898000 | USD | 20210512 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 2049000 | USD | 20210512 | Open filing evidence |
Protein Detection Segment
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=mrvi:ProteinDetectionSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-01-01 – 2021-12-31 | 18959000 | USD | 20240229 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 5283000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 18959000 | USD | 20221104 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 7046000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 13676000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 6630000 | USD | 20220506 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 22881000 | USD | 20230228 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 6089000 | USD | 20211115 | Open filing evidence |
| 2020-01-01 – 2020-09-30 | 16404000 | USD | 20211115 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 4117000 | USD | 20210811 | Open filing evidence |
| 2020-01-01 – 2020-06-30 | 10315000 | USD | 20210811 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 6198000 | USD | 20210512 | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 26122000 | USD | 20220301 | Open filing evidence |
Protein Detection Segment · Operating Segments
Statement Business Segments · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=mrvi:ProteinDetectionSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-01-01 – 2021-03-31 | 6630000 | USD | 20220506 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 6198000 | USD | 20210512 | Open filing evidence |
Protein Detection Segment · Latin And Central America
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=mrvi:ProteinDetectionSegmentMember;srt:StatementGeographicalAxis=mrvi:LatinAndCentralAmericaMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-01-01 – 2021-12-31 | 123000 | USD | 20240229 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 29000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 123000 | USD | 20221104 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 44000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 94000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 50000 | USD | 20220506 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 149000 | USD | 20230228 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 40000 | USD | 20210512 | Open filing evidence |
Protein Detection Segment · Asia Pacific
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=mrvi:ProteinDetectionSegmentMember;srt:StatementGeographicalAxis=srt:AsiaPacificMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-07-01 – 2021-09-30 | 795000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 3068000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 1360000 | USD | 20210512 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 1107000 | USD | 20210512 | Open filing evidence |
Protein Detection Segment · North America
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=mrvi:ProteinDetectionSegmentMember;srt:StatementGeographicalAxis=srt:NorthAmericaMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-01-01 – 2021-12-31 | 11016000 | USD | 20240229 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 3067000 | USD | 20221104 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 11016000 | USD | 20221104 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 4197000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 7949000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 3752000 | USD | 20220506 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 13343000 | USD | 20230228 | Open filing evidence |
Protein Detection Segment · EMEA
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=mrvi:ProteinDetectionSegmentMember;srt:StatementGeographicalAxis=us-gaap:EMEAMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-01-01 – 2021-12-31 | 4752000 | USD | 20240229 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 1892000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 3360000 | USD | 20220805 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 1468000 | USD | 20210512 | Open filing evidence |
| 2020-01-01 – 2020-03-31 | 1622000 | USD | 20210512 | Open filing evidence |
Tri Link Segment
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=mrvi:TriLinkSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 34669000 | USD | 20260807 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 82145000 | USD | 20260807 | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 119787000 | USD | 20260226 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 31085000 | USD | 20260807 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 59835000 | USD | 20260807 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 196345000 | USD | 20260226 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 224769000 | USD | 20260226 | Open filing evidence |